These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 9439554)

  • 1. The effects of gliclazide and other sulfonylureas on low-density lipoprotein oxidation in vitro.
    O'Brien RC; Luo M
    Metabolism; 1997 Dec; 46(12 Suppl 1):22-5. PubMed ID: 9439554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo antioxidant properties of gliclazide.
    O'Brien RC; Luo M; Balazs N; Mercuri J
    J Diabetes Complications; 2000; 14(4):201-6. PubMed ID: 11004429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of tolbutamide, glyburide and glipizide administered supraspinally on CA3 hippocampal neuronal cell death and hyperglycemia induced by kainic acid in mice.
    Kim CH; Park SH; Sim YB; Kim SS; Kim SJ; Lim SM; Jung JS; Suh HW
    Brain Res; 2014 May; 1564():33-40. PubMed ID: 24713348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gliclazide decreases cell-mediated low-density lipoprotein (LDL) oxidation and reduces monocyte adhesion to endothelial cells induced by oxidatively modified LDL.
    Desfaits AC; Serri O; Renier G
    Metabolism; 1997 Oct; 46(10):1150-6. PubMed ID: 9322798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of gliclazide on low-density lipoprotein oxidizability and atherosclerosis in cholesterol-fed rabbits.
    Nomura H; Naito M; Kodama M; Kato Y; Iguchi A
    J Atheroscler Thromb; 2000; 7(2):104-9. PubMed ID: 11426581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Free radical scavenging activity of sulfonylureas: a clinical assessment of the effectiveness of gliclazide].
    Jennings PE; Belch JJ
    Ter Arkh; 2001; 73(4):27-31. PubMed ID: 11494442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antioxidant supplementation effects on low-density lipoprotein oxidation for individuals with type 2 diabetes mellitus.
    Anderson JW; Gowri MS; Turner J; Nichols L; Diwadkar VA; Chow CK; Oeltgen PR
    J Am Coll Nutr; 1999 Oct; 18(5):451-61. PubMed ID: 10511327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microvascular permeability with sulfonylureas in normal and diabetic hamsters.
    Bouskela E; Cyrino FZ; Conde CM; Garcia AA
    Metabolism; 1997 Dec; 46(12 Suppl 1):26-30. PubMed ID: 9439555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Photohemolytic potency of oral antidiabetic drugs in vitro: effects of antioxidants and a nitrogen atmosphere.
    Selvaag E
    Photodermatol Photoimmunol Photomed; 1996 Aug; 12(4):166-70. PubMed ID: 9017793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potentiating effect of the simultaneous administration of tolbutamide, glibenclamide, and gliclazide on the development of alloxan-induced diabetes in rats.
    Katsumata K; Katsumata Y
    Horm Metab Res; 1990 Jan; 22(1):51-2. PubMed ID: 2106472
    [No Abstract]   [Full Text] [Related]  

  • 11. Gliclazide decreases low-density lipoprotein oxidation and monocyte adhesion to the endothelium.
    Renier G; Desfaits AC; Serri O
    Metabolism; 2000 Feb; 49(2 Suppl 1):17-22. PubMed ID: 10693915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The oral anti-diabetic agent, gliclazide, inhibits oxidized LDL-mediated LOX-1 expression, metalloproteinase-9 secretion and apoptosis in human aortic endothelial cells.
    Li L; Renier G
    Atherosclerosis; 2009 May; 204(1):40-6. PubMed ID: 18801483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutical concentrations of tolbutamide, glibenclamide, gliclazide and gliquidone at different glucose levels: in vitro effects on pancreatic A- and B-cell function.
    Gregorio F; Ambrosi F; Cristallini S; Pedetti M; Filipponi P; Santeusanio F
    Diabetes Res Clin Pract; 1992 Dec; 18(3):197-206. PubMed ID: 1289021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events.
    Douros A; Yin H; Yu OHY; Filion KB; Azoulay L; Suissa S
    Diabetes Care; 2017 Nov; 40(11):1506-1513. PubMed ID: 28864502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression by 2-ketoisocaproate of the insulinotropic action of hypoglycemic sulfonylureas.
    Malaisse WJ; Mathias PC; Malaisse-Lagae F; Sener A
    Res Commun Chem Pathol Pharmacol; 1985 Feb; 47(2):265-84. PubMed ID: 3922019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetic endothelial dysfunction: effect of free radical scavenging in Type 2 diabetic patients.
    De Mattia G; Laurenti O; Fava D
    J Diabetes Complications; 2003; 17(2 Suppl):30-5. PubMed ID: 12623166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gliclazide decreases vascular smooth muscle cell dysfunction induced by cell-mediated oxidized low-density lipoprotein.
    Mamputu JC; Renier G
    Metabolism; 2001 Jun; 50(6):688-95. PubMed ID: 11398146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study.
    Abdelmoneim AS; Eurich DT; Gamble JM; Johnson JA; Seubert JM; Qiu W; Simpson SH
    Diabetes Obes Metab; 2014 Jan; 16(1):22-9. PubMed ID: 23802997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monocyte adhesion in diabetic angiopathy: effects of free-radical scavenging.
    Renier G; Mamputu JC; Desfaits AC; Serri O
    J Diabetes Complications; 2003; 17(2 Suppl):20-9. PubMed ID: 12623165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Free radical scavenging activity of sulfonylureas: a clinical assessment of the effect of gliclazide.
    Jennings PE; Belch JJ
    Metabolism; 2000 Feb; 49(2 Suppl 1):23-6. PubMed ID: 10693916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.